Bio-Rad Laboratories Class B
BIO.B
12 hedge funds and large institutions have $82.3M invested in Bio-Rad Laboratories Class B in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 0 closing their positions.
20% more funds holding
Funds holding: 10 → 12 (+2)
17% more capital invested
Capital invested by funds: $70.6M → $82.3M (+$11.7M)
0.01% more ownership
Funds ownership: 2.16% → 2.18% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GI
GAMCO Investors
Greenwich,
Connecticut
|
+$234K |
| 2 |
OPCM
Osborne Partners Capital Management
San Francisco,
California
|
+$214K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$52.8K |
| 4 |
TM
Tikvah Management
Charlotte,
North Carolina
|
+$7.54K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$754 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TM
1
Tikvah Management
Charlotte,
North Carolina
| $73.4M | +$7.54K | +10 | +0% |
|
|
CL
2
CSS LLC
Chicago,
Illinois
| $5.5M | – | – | – |
|
3
Renaissance Technologies
New York
| $1.75M | – | – | – |
|
4
Morgan Stanley
New York
| $514K | – | – | – |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $336K | +$754 | +1 | +0.2% |
|
|
GI
6
GAMCO Investors
Greenwich,
Connecticut
| $230K | +$234K | +310 | New |
|
|
OPCM
7
Osborne Partners Capital Management
San Francisco,
California
| $211K | +$214K | +284 | New |
|
|
GAM
8
Gemmer Asset Management
Walnut Creek,
California
| $207K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $72K | +$52.8K | +70 | +259% |
|
10
Wells Fargo
San Francisco,
California
| $42K | – | – | – |
|
11
Osaic Holdings
Scottsdale,
Arizona
| $38K | – | – | – |
|
12
Bank of America
Charlotte,
North Carolina
| $28K | – | – | – |
|
BIO.B Hedge Fund Activity: Q3 2021 in Review
12 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class B (BIO.B) for Q3 2021, worth a combined $82.3M — up 17% from $70.6M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BIO.B positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was GAMCO Investors, opening a new position worth an estimated $234K.
- 12 institutional investors held Bio-Rad Laboratories Class B (BIO.B) as of Q3 2021, up from 10 in Q2 2021.
- Funds reported $82.3M of Bio-Rad Laboratories Class B stock for Q3 2021, up 17% quarter-over-quarter.
- 2 funds opened new Bio-Rad Laboratories Class B positions in Q3 2021 and 0 closed out, a net change of +2 holders.
- The largest Bio-Rad Laboratories Class B buyer in Q3 2021 was GAMCO Investors, an estimated $234K added.
Based on aggregated 13F filings for Q3 2021.